で公開中です！詳しく見る

Janux Therapeutics

JANX

時価総額 $10.1億

16.51 USD

-0.81

4.68%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

16.51

0.00

0%

1日

-4.68%

5日間

-9.73%

1か月

1.6%

3か月

4.23%

6か月

8.69%

年初来

20.95%

1年

-39.3%

5年間

-22.27%

10年間

-34.35%

概要： Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

従業員数： 113

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 40%

ニュートラル 40%

ネガティブ 20%

ポジティブ

Zacks Investment Research

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

ニュートラル

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC). The program is initially being developed in combination with JANX007, with the goal of furthe.

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

ポジティブ

Zacks Investment Research

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

ネガティブ

Zacks Investment Research

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

ニュートラル

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update. "During the second quarter we continued to execute across our clinical portfolio while preparing for multiple upcoming milestones," said David Campbell, Ph.D., President and Chief Executive Officer of Janux. "Enrollment con.

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

ポジティブ

Zacks Investment Research

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know

ポジティブ

Zacks Investment Research

Here's Why You Should Add JANX Stock to Your Portfolio Now

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.

Here's Why You Should Add JANX Stock to Your Portfolio Now

ネガティブ

Zacks Investment Research

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago.

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

ニュートラル

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., Pr.

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

ポジティブ

Zacks Investment Research

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています